AHL
RLAY icon

Abel Hall LLC’s Relay Therapeutics RLAY Stock Holding History

Abel Hall LLC’s Portfolio RLAY Stock Details RLAY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$344K Buy
18,362
+125
+0.7% +$1.81K 0.06% 408
2026
Q1 		$181K Buy
18,237
+5,253
+40% +$47K 0.04% 635
2025
Q4 		$110K Buy
12,984
+1,809
+16% +$12.9K 0.03% 605
2025
Q3 		$58.3K Buy
+11,175
New +$42.6K 0.02% 296

Other funds holding RLAY

SIAU
SB Investment Advisers (UK) London, United Kingdom $7.66B AUM 20.12% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
CC
Casdin Capital New York $2B AUM 147.21% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
CC
Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
NI
Nextech Invest Zurich, Switzerland $2.11B AUM 413.84% 1-Year Est. Return

Abel Hall LLC's RLAY Position: Q2 2026 in Review

Abel Hall LLC increased its Relay Therapeutics (RLAY) stake by 0.69% in Q2 2026, buying an estimated $1.81K and bringing the position to 18,362 shares worth $344K. The position accounts for 0.06% of the portfolio, ranked #408.

Abel Hall LLC first reported a position in RLAY in Q3 2025 and has held it in 4 quarters since. 259 funds tracked by Wall St. Rank hold RLAY as of Q2 2026.

  • Abel Hall LLC held 18,362 shares of Relay Therapeutics worth $344K as of Q2 2026.
  • Abel Hall LLC bought 125 Relay Therapeutics shares in Q2 2026, an estimated $1.81K.
  • Relay Therapeutics made up 0.06% of Abel Hall LLC's portfolio in Q2 2026, its #408 holding.
  • Abel Hall LLC first reported a position in Relay Therapeutics in Q3 2025 and has held it in 4 quarters since.
  • 259 funds tracked by Wall St. Rank held Relay Therapeutics as of Q2 2026.

Based on Abel Hall LLC's 13F filing for Q2 2026, filed 24 Jul 2026.